GlassScriptPhysician profile
Frank A Don
NPI 1821248022
$269,065.14
in general payments reported to CMS, 2019-2025
50 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $24K · 2021: $29K · 2022: $33K · 2023: $41K · 2024: $40K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Food and Beverage: $15K · Travel and Lodging: $6,260 · Consulting Fee: $2,588 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,142.50 |
| Food and Beverage | $15,142.32 |
| Travel and Lodging | $6,259.74 |
| Consulting Fee | $2,587.50 |
| Education | $190.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209,245.34 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $21,201.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $16,756.97 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $3,732.40 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $2,894.39 | 2019-2025 | Tremfya |
| Amgen INC. | $2,156.35 | 2019-2025 | Otezla, Otezla |
| Epi Health, LLC | $1,543.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,447.98 | 2019-2025 | |
| Lilly USA, LLC | $1,190.48 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $1,157.97 | 2019-2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,035.99 | 2025 | |
| Ucb, INC. | $993.41 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $893.75 | 2019-2025 | Cabtreo, Siliq, Targretin |
| Incyte Corporation | $738.01 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $472.30 | 2019-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $442.18 | 2019-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $391.77 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $356.69 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $334.67 | 2019-2025 | Nemluvio, Aklief |
| Organogenesis INC. | $317.38 | 2021-2025 | Puraply Wound Matrix, Via Matrix, Novachor |
| Celgene Corporation | $314.68 | 2019 | |
| Kyowa Kirin, INC. | $228.67 | 2020-2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $219.04 | 2019-2025 | |
| Genentech USA, INC. | $203.61 | 2019-2021 | |
| Allergan, INC. | $156.23 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $91.75 | 2021-2025 | Valchlor |
| Merck Sharp & Dohme LLC | $83.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.64 | 2024-2025 | Spevigo |
| Almirall LLC | $66.40 | 2021-2024 | Klisyri |
| Fresenius Kabi USA, LLC | $40.43 | 2023-2024 | |
| Organon LLC | $39.18 | 2024-2025 | Nexplanon, Vtama |
| Taro Pharmaceuticals USA, INC. | $24.56 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.55 | 2021 | |
| Encore Dermatology INC. | $23.62 | 2019 | |
| Nabriva Therapeutics, Plc | $21.85 | 2021 | |
| Boston Scientific Corporation | $21.11 | 2019 | |
| Bausch Health US, LLC | $18.34 | 2021 | |
| Promius Pharma LLC | $18.13 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.08 | 2020 | |
| Kerecis Limited | $15.11 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Botanix Sb INC | $14.72 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $13.75 | 2025 | Daxi |
| Sebela Pharmaceuticals INC. | $13.36 | 2019 | |
| Journey Medical Corporation | $12.35 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Don listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.